| Patient | Booker T. Washington |
|---|---|
| Date of birth | 1856-04-05 |
| Identifiers | MRN HR-NI017-SYN-TD; SSN (made up) 000-17-2284 |
| Document date | 1915-06-01 |
| Author | Lorraine Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-week check after the losartan increase and dapagliflozin start. [S]
Mr. Washington returns three weeks after losartan was increased to 100 mg and dapagliflozin started. His home readings now run in the 140s and 150s over 90s. He has had no headaches for two weeks and palpitations are rare. He passes a little more urine in the daytime since starting dapagliflozin but has had no genital itching, thirst, or lightheadedness on standing. He has taken no pain relievers. On two trips he ate restaurant meals most days and has begun asking for dishes without added salt. [S]
| Element | Detail |
|---|---|
| Home blood pressure | 140s to 150s over 90s |
| Symptoms | No headaches for two weeks; palpitations rare |
| Medication tolerance | Slightly more daytime urine; no genital itching, thirst, or lightheadedness |
| Medicines | Every dose taken; no NSAIDs or other over-the-counter products |
| Diet | Asking for low-salt dishes on the road |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy slightly better; no weight change |
| Cardiovascular | Negative | No chest pain or ankle swelling; palpitations rare |
| Genitourinary | Positive | Slightly more daytime urine; up twice a night; no genital itching or dysuria |
| Neurological | Negative | No headache or lightheadedness on standing |
| Eyes | Negative | Reading blur unchanged; no sudden vision change |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Amlodipine 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 | active | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 to 1915-05-11 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-11 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-11 | active | S |
| Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily | One-half tablet by mouth daily | Oral route | 1915-06-01 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1915-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1915-06-01 | Body height | 170 | cm | S |
| 1915-06-01 | Body weight | 70 | kg | S |
| 1915-06-01 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 1915-06-01 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1915-06-01 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 1915-06-01 | Heart rate | 78 | /min | S |
| 1915-06-01 | Respiratory rate | 16 | /min | S |
| 1915-06-01 | Body temperature | 36.8 | Cel | S |
| 1915-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1915-06-01 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1915-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1915-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 | mmol/L | 22-29 mmol/L | Normal | S |
| 1915-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 38 | mg/dL | 6-24 mg/dL | High | S |
| 1915-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 2.4 | mg/dL | 0.74-1.35 mg/dL | High | S |
| 1915-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 30 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1915-06-01 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
Vital signs recorded on 1915-06-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 148/92 mmHg, the average of two seated readings after five minutes' rest |
| Heart | Regular rhythm, rate 78; S4 |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Severe hypertension with hypertensive kidney disease; synthetic modern diagnosis linked to the documented 1804 blood pressure of 220/150 | active | confirmed | I12.9 | S — Synthetic active diagnosis for the teaching episode; the 1915 findings remain D and the retrospective diagnosis remains R. |
| Chronic kidney disease stage G3b A3 (severely increased albuminuria), attributed to hypertensive nephrosclerosis | active | confirmed | N18.32 | S — Synthetic diagnosis supported by small echogenic kidneys and albuminuria; linked to the documented 1915 diagnosis of Bright's disease. |
| Hypertensive retinopathy, both eyes, without papilledema | active | confirmed | H35.033 | S — Synthetic funduscopic finding that echoes the documented failing vision. |
| Mild anemia of chronic kidney disease, iron replete; monitor | active | confirmed | D63.1 | S — Synthetic finding from the baseline hemoglobin and iron studies. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine (basic metabolic panel) | 2 to 4 weeks after starting or titrating losartan, dapagliflozin, or a diuretic; with each eGFR draw | Completed today | Three weeks after the losartan increase and dapagliflozin start. Potassium 4.9, creatinine 2.4 mg/dL (up 14 percent from baseline), eGFR 30 (down 17 percent), within the 30 percent accepted |
| Laboratory | Potassium, sodium, and creatinine after starting chlorthalidone | 2 to 4 weeks after a diuretic start | Due | Chlorthalidone starts today; drawn at the four-week check |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Due | Urine albumin-creatinine ratio at the four-week check, once the regimen is complete |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Due | At the six-month review (deviation recorded last visit) |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 148/92 mmHg |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70 kg; S4 |
| Medication safety | Dapagliflozin tolerance | Each visit while starting | Completed today | No genital infection, volume depletion, or lightheadedness |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs; doses checked for eGFR 30 |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Home log reviewed; low-salt choices on the road |
Goal progress:
Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026)
Follow-up: Four-week check with potassium, sodium, creatinine, and a urine albumin-creatinine ratio after starting chlorthalidone. Next scheduled visit 1915-06-29: four-week check after adding chlorthalidone. [S]